Sucralphate-technetium scintigraphy in inflammatory bowel disease: experience in 23 patients.
Serial abdominal scanning after the oral administration of sucralphate-99mTc was performed in order to determine the extent of active inflammatory bowel disease in 15 patients with Crohn's disease and in 8 patients with ulcerative colitis. Scintigraphic data were compared with those obtained by endoscopy and radiology in all patients. True positive scans were obtained in 6 (40%) patients with Crohn's disease and in 3 (38%) patients with ulcerative colitis. Overall, sensitivity was higher in colonic disease than that in ileal disease. In 4 (17%) patients, false negative scans were obtained and in the remaining 10 (44%) patients, localisation of the inflammatory bowel disease by the isotope was completely inaccurate. Since sensitivity of the sucralphate-99mTc scintigraphy appears to be low, its widespread use in the screening for inflammatory bowel disease or in assessing the extent of disease involvement cannot be advocated at this moment.
Zeijen
R N
RN
van der Pol
H A
HA
Teule
G J
GJ
Bos
L P
LP
Flendrig
J A
JA
Engels
L G
LG
D000328:Adult; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000000981:diagnostic imaging*; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D013392:Sucralfate; D013667:Technetium
D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; C038248:technetium Tc 99m sucralfate; D013392:Sucralfate; D013667:Technetium